Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to
be in widespread clinical use especially for management of tumors of the ovary, testes, and …

The vast amount of basic research on platinum coordination complexes has produced, over
the past 25 years, several thousand new molecules for preclinical screening and 28 …

Of the new generation platinum compounds that have been evaluated, those with the 1, 2-
diaminocyclohexane carrier ligand–including oxaliplatin–have been focused upon in recent …

Thirty years after the onset of the first clinical studies with cisplatin, the development of
antineoplastic platinum drugs continues to be a productive field of research. This article …

PURPOSE: To evaluate the efficacy and safety of an oxaliplatin, fluorouracil (5-FU), and
folinic acid (FA) combination in patients with metastatic or advanced gastric cancer (M/AGC) …

The aim of this study was to determine the influence of oxaliplatin scheduling on the onset of
peripheral neurotoxicity and ototoxicity in a rat model. Animals were treated with four …

Oxaliplatin is a platinum compound that inhibits DNA synthesis, primarily by causing
intrastrand cross-links in DNA. Oxaliplatin has a broad spectrum of antineoplastic activity …

Oxaliplatin is the first clinically available diaminocyclohexane platinum coordination
complex. The drug is non-cross-resistant with cisplatin or carboplatin and is one of the few …

Cisplatin, carboplatin, nedaplatin, and oxaliplatin are widely used in contemporary
oncology; however, their ototoxic and neurotoxic side effects are quite different as discussed …

Oxaliplatin (Eloxatin™), a recently developed third-generation cisplatin analogue with a 1, 2-
diaminocyclohexane (DACH) carrier ligand, has displayed preclinical and clinical activity in …